



🔍 Use a keyword, test name or number

## Itraconazole, Serum or Plasma

**TEST: 700833** CPT: 80189

Synonyms • Sporanox®

### SPECIMEN REQUIREMENTS

Specimen Serum (preferred) **or** plasma

Volume 1 mL

Minimum Volume 0.5 mL

Container Red-top tube **or** lavender-top (EDTA) tube

Collection Transfer separated serum or plasma to a plastic transport tube. **Do not use a gel barrier tube.** The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.

Storage Instructions Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen.

Stability Requirements

Temperature	Period
Room temperature	14 days

Temperature	Period
Refrigerated	14 days
Frozen	14 days

Causes for Rejection      Gel barrier tubes

## TEST DETAILS

**Use**      Treatment of susceptible fungal infections in immunocompromised and immunocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis and onychomycosis of the toenail and fingernail. It has been recommended that routine monitoring occur during the first week of therapy to ensure therapeutic levels are achieved for each individual and to continue monitoring if clinical presentations do not improve or decline.

**Limitations**      This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

**Methodology**      Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

**References**      Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. *J Antimicrob Chemother.* 2014 May;69(5):1162-1176. [PubMed 24379304](#)  
Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. *Antimicrob Agents Chemother.* 2009 Jan;53(1):24-34. [PubMed 18955533](#)  
*Clinical Primer: Potential Hepatic Complications With Triazole Therapy.* Tinton Falls, NJ: Fallon Medica LLC; 2010.

including the LOINC Manual, which can be downloaded at [LOINC.org/downloads/files/LOINCManual.pdf](https://LOINC.org/downloads/files/LOINCManual.pdf)

[Privacy Statement](#)      [Terms of Use](#)      [Notice of Nondiscrimination](#)

[Combatting Modern Slavery and Human Trafficking Statement](#)

© 2022 Laboratory Corporation of America® Holdings. All Rights Reserved.